MedTrace Logo

PK Study of Multi-dose Trazodone Hydrochloride Prolonged-released Tablets in Healthy Chinese

NCT02785614 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2018-09-05

No results posted yet for this study

Summary

The main objective is to evaluate the pharmacokinetics comparative studies in a single dose, multiple dose

Conditions

Interventions

DRUG

trazodone hydrochloride prolonged-release tablet

150 mg, oral administration, 1 per day

DRUG

trazodone hydrochloride tablet

50mg, oral administration 3 times per day

Sponsors & Collaborators

  • Lee's Pharmaceutical Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2017-11-30
Completion
2018-01-04

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02785614 on ClinicalTrials.gov